The company said in a filing that it may repurchase shares from time to time though the open market, in privately negotiated transactions or other means.
On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.
The study also demonstrated complete and durable responses in patients with recurrent intermediate-risk disease, along with encouraging recurrence-free outcomes in high-risk disease, the company said.
The Vanguard 0-3 Month Treasury Bill ETF invests in ultra-short U.S. Treasury securities, giving investors a way to earn short-term government yields while keeping interest-rate risk and portfolio volatility low.
For fiscal 2026, the company now expects net sales growth of 6% to 7%, and diluted earnings per share of $28.05 to $28.55, below a Wall Street estimate of $28.58.
The company said upon closing of the final transaction with an institutional investor its outstanding debt will be reduced by approximately $37.9 million.
Bloomberg reported on Thursday that the company’s ordering and shipping systems are still offline following a cyberattack, claimed by pro-Iranian digital activist group Handala, on Wednesday.
The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.
The company said its pilots will visit its California facility later this year to conduct the testing required to validate the aircraft for commercial service.
The Wall Street Journal reported, citing people familiar with the matter, that the Qatari-backed investment fund Irth Capital Management has submitted a bid to take Papa John's private.
UiPath’s Short interest has climbed to 15.7%, nearly double mid-December levels, prompting some traders to expect a short squeeze if the earnings report beats expectations.
